25 episodios

Interviews and highlights from the 2017 AACR conference.

AACR 2017 ecancer

    • Medicina

Interviews and highlights from the 2017 AACR conference.

    • video
    Neratinib in HER2 or HER3 mutant solid tumours

    Neratinib in HER2 or HER3 mutant solid tumours

    Dr Hyman speaks with ecancer at AACR 2017 to discuss results of the phase II SUMMIT trial of neratinib, which you can read more about here, or watch the press conference in which these results were presented.

    He describes the response of patients with HER2 mutations to neratinib, most notably in breast, cervical and biliary cancers, and considers the influence of tumour type and specific mutation to explain the lack of responses in patients with HER3 mutations and HER2 colorectal tumours.

    • 2 min
    • video
    Durable responses to avelumab in patients with Merkel cell carcinoma

    Durable responses to avelumab in patients with Merkel cell carcinoma

    Dr Kaufman speaks with ecancer at AACR 2017 about the effectiveness of anti-PD-L1 avelumab in treating Merkel cell carcinoma (MCC) in patients who had been previously treated with chemotherapy.

    He describes results from 88 patients with metastatic disease, who at 6 months follow-up had 31% response, and 33% response at 1 year.

    Dr Kaufman notes the recent FDA approval of avelumab in this setting, and considers other possible applications.

    • 2 min
    • video
    Olaparib and temozolomide for relapsed small cell lung cancer

    Olaparib and temozolomide for relapsed small cell lung cancer

    Dr Farago speaks with ecancer at AACR 2017 about results from a phase I/II study of treating patients with small cell lung cancer (SCLC) following relapsed after chemotherapy.

    She describes the rationale of adding olaparib, a PARP inhibitor preventing DNA repair, to temozolomide which induces single strand breaks, with a hopeful synergy for controllable cell death within tumours.

    Dr Farago describes the doses in the trial as well tolerated, with a response rate of 48% and a median PFS of 5.6 months.

    She also highlights the utility of patient derived xenografts to chart patient responses through time, and identify stages of resistance and response.

    • 4 min
    • video
    Redefining tamoxifen for breast cancer

    Redefining tamoxifen for breast cancer

    Dr Das speaks with ecancer at AACR 2017 about the effect of tamoxifen before surgery on the genome of breast cancer cells.

    He reports that binding of oestrogen receptors deactivates p53, a tumour suppressor gene, based on sequencing after four weeks of tamoxifen therapy.

    Dr Das describes these findings pointing towards p53 activation as a predictor of tamoxifen response, with further trials to confirm utility in stratifying patients with triple negative breast cancer.

    • 7 min
    • video
    Final overall survival analysis of MONARCH 1

    Final overall survival analysis of MONARCH 1

    Dr Rugo speaks with ecancer at AACR 2017 about the final analysis of MONARCH 1, a phase II trial of abemaciclib for advanced HR /HER2- breast cancer following chemotherapy.

    She summarises the cell cycle action of CDK4/6 inhibitors, noting cross-activity with oestrogen receptors, and the differing actions of related treatments ribociclib and palbociclib.

    Dr Rugo describes the treatment history of trial participants, and outlines the improvements in PFS with easily-managed adverse effects.

    She also notes effects of abemaciclib on kidney tububle function, which is "meaningless on a clinical basis".

    • 8 min
    • video
    Understanding response and resistance to cancer therapy: Lessons learned from melanoma

    Understanding response and resistance to cancer therapy: Lessons learned from melanoma

    Dr Wargo speaks with ecancer at AACR 2017 about understanding the mechanisms of resistance in treating tumours, considering the influence of epigenetics, the tumour microenvironment and microbiota among others.

    The influence of the microbiome on cancer risk and treatment response was reviewed in an ecancer article last year, and she describes how research in mouse models translates to human trials.

    She considers faecal transplant, which is proving effective in managing C. diff infections, as a route for treating cancers in the near future.

    Dr Wargo goes on to discuss presentations from coworkers at the conference, including targeting stage III melanoma with BRAF inhibition before and after surgery.

    • 8 min

Top podcasts de Medicina

Más de ecancer